TreatSMA

Do you know about the Council for Disabled Children?

TreatSMA is signposting families to the Legal Handbook 3rd edition uploaded by the Council for Disabled Children.

We thought this maybe useful.

“A legal handbook is an accessible guide to the legal rights of disabled children and their families in England. There are twelve chapters within the handbook on topics including: education; health; children’s services; transition into adulthood; housing; carers and welfare benefits.

The legal handbook explains what public bodies must do to support disabled children and that which they should do. The handbook aims to empower disabled children and their families through providing a greater understanding of their rights and entitlements

The handbook is essential for families of disabled children, their advocates, professionals and practitioners in voluntary, independent or statutory services as well as lawyers, social & health care professionals, students and academics.

Read the handbook here: https://buff.ly/2XRJEiF

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more